[go: up one dir, main page]

AR072933A1 - Sistema de administracion de drogas con contenido de progestina - Google Patents

Sistema de administracion de drogas con contenido de progestina

Info

Publication number
AR072933A1
AR072933A1 ARP090103070A ARP090103070A AR072933A1 AR 072933 A1 AR072933 A1 AR 072933A1 AR P090103070 A ARP090103070 A AR P090103070A AR P090103070 A ARP090103070 A AR P090103070A AR 072933 A1 AR072933 A1 AR 072933A1
Authority
AR
Argentina
Prior art keywords
dosage form
individual dosage
form according
film matrix
protective agent
Prior art date
Application number
ARP090103070A
Other languages
English (en)
Inventor
Ildiko Terebesi
Stefan Bracht
Sascha General
Adrian Funke
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2009/000904 external-priority patent/WO2009100871A2/en
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of AR072933A1 publication Critical patent/AR072933A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Botany (AREA)
  • Gynecology & Obstetrics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Reivindicacion 1: Una forma de dosificacion individual caracterizada porque comprende una matriz de película delgada soluble en agua, donde: a) dicha matriz de película comprende al menos un polímero de matriz soluble en agua; b) dicha matriz de película comprende partículas, donde dichas partículas comprenden al menos una progestina y al menos un agente protector, y donde dichas partículas tienen un tamano de partícula d90, < 280 micrometros; y c) dicha matriz de película tiene un grosor <= 300 micrometros. Reivindicacion 5: La forma de dosificacion individual de acuerdo con cualquiera de las reivindicaciones precedentes, caracterizada porque dicho agente protector es un polimetacrilato cationico. Reivindicacion 6: La forma de dosificacion individual de acuerdo con cualquiera de las reivindicaciones 1-4, caracterizada porque dicho agente protector es una cera. Reivindicacion 16: La forma de dosificacion individual de acuerdo con cualquiera de las reivindicaciones precedentes, caracterizada porque dicha forma de dosificacion individual también comprende al menos un estrogeno. Reivindicacion 24: Una forma de dosificacion individual de acuerdo con cualquiera de las reivindicaciones 16-21, caracterizada porque es para la inhibicion de la ovulacion en un mamífero hembra. Reivindicacion 25: Una forma de dosificacion individual de acuerdo con cualquiera de las reivindicaciones 16-21, caracterizada porque es para proveer anticoncepcion en un mamífero hembra.
ARP090103070A 2008-08-08 2009-08-10 Sistema de administracion de drogas con contenido de progestina AR072933A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08162105 2008-08-08
PCT/EP2009/000904 WO2009100871A2 (en) 2008-02-13 2009-02-10 Drug delivery system with stabilising effect

Publications (1)

Publication Number Publication Date
AR072933A1 true AR072933A1 (es) 2010-09-29

Family

ID=40210465

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090103070A AR072933A1 (es) 2008-08-08 2009-08-10 Sistema de administracion de drogas con contenido de progestina

Country Status (23)

Country Link
US (1) US20110293720A1 (es)
EP (1) EP2331067A1 (es)
JP (1) JP2011530499A (es)
KR (1) KR20110044752A (es)
CN (1) CN102119021A (es)
AR (1) AR072933A1 (es)
AU (1) AU2009279053A1 (es)
BR (1) BRPI0917030A2 (es)
CA (1) CA2732211A1 (es)
CO (1) CO6351709A2 (es)
CR (1) CR20110072A (es)
DO (1) DOP2011000049A (es)
EA (1) EA201100304A1 (es)
EC (1) ECSP11010815A (es)
IL (1) IL210590A0 (es)
MA (1) MA32538B1 (es)
MX (1) MX2011001519A (es)
PE (1) PE20110573A1 (es)
SV (1) SV2011003835A (es)
TW (1) TW201008569A (es)
UY (1) UY32041A (es)
WO (1) WO2010015713A1 (es)
ZA (1) ZA201101737B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010086989A1 (ja) 2009-01-29 2010-08-05 日東電工株式会社 口腔内フィルム状基剤及び製剤
HUP0900698A2 (en) * 2009-11-06 2011-06-28 Richter Gedeon Nyrt Pharmaceutical compositions of enhanced stability containing drospirenone and ethynyl estradiol and process for their preparation
JP5588688B2 (ja) * 2010-01-28 2014-09-10 日東電工株式会社 フィルム状製剤
JP5751868B2 (ja) 2010-03-30 2015-07-22 日東電工株式会社 フィルム状製剤及びその製造方法
JP2011207847A (ja) * 2010-03-30 2011-10-20 Nitto Denko Corp フィルム状製剤及びその製造方法
US11351122B1 (en) 2010-07-28 2022-06-07 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
JP6062437B2 (ja) 2011-09-09 2017-01-18 フィリップ・モーリス・プロダクツ・ソシエテ・アノニム 香味送出材料を含む喫煙物品
US9044734B2 (en) 2011-09-23 2015-06-02 Basf Se Diesel oxidation catalyst with layered structure containing ceria composition as palladium support material for enhanced HC and CO gas conversion
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CA2856520C (en) 2011-11-23 2021-04-06 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
JP5841433B2 (ja) 2012-01-11 2016-01-13 日東電工株式会社 口腔内フィルム状基剤及び製剤
JP5952646B2 (ja) * 2012-06-07 2016-07-13 救急薬品工業株式会社 口腔内溶解型フィルム製剤
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10668156B2 (en) 2012-06-22 2020-06-02 Basf Se Active-ingredient-containing solid dispersions based on diethylaminoethyl methacrylate copolymers
EP2863953A1 (de) * 2012-06-22 2015-04-29 Basf Se Wirkstoffhaltige festen dispersionen auf basis von diethylaminoethylmethacrylat-copolymeren
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CN103040725B (zh) * 2012-12-26 2015-01-21 武汉九珑人福药业有限责任公司 一种利用研磨改善屈螺酮溶出的方法及屈螺酮固体分散体
JP6084468B2 (ja) * 2013-01-24 2017-02-22 アリメント工業株式会社 シビレ緩和持続性唾液分泌促進剤、その製造方法、及びシビレ緩和持続性唾液分泌促進食品
KR101407922B1 (ko) * 2013-11-14 2014-06-17 주식회사 서울제약 약리학적 활성 성분을 포함하는 다공성 구강붕해필름 및 이의 제조방법
MX2016014281A (es) 2014-05-22 2017-02-22 Therapeuticsmd Inc Formulaciones y terapias de reemplazo de combinación de hormonas naturales.
BR112016029338A2 (pt) 2014-07-29 2017-08-22 Therapeuticsmd Inc creme transdérmico
US20160243036A1 (en) * 2015-02-25 2016-08-25 Intelgenx Corp. Film dosage forms containing amorphous active agents
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
MX2018011705A (es) 2016-04-01 2019-06-10 Therapeuticsmd Inc Composicion farmaceutica de hormona esteroide.
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
CN108606963B (zh) * 2017-12-27 2021-05-18 上海长海医院 含有屈螺酮和雌激素的复方避孕贴、制备方法及应用
CN108186586B (zh) * 2018-03-01 2020-12-29 常州市第四制药厂有限公司 一种烯丙雌醇片剂及其制备方法
CN108853017B (zh) * 2018-09-17 2021-03-02 西安力邦医药科技有限责任公司 一种雌三醇纳米口服制剂的组方与制备工艺
EP3954364A1 (en) * 2020-08-14 2022-02-16 Chemo Research, S.L. New modified release oral contraceptive composition
MX2023003432A (es) 2020-09-29 2023-08-04 Millicent Pharma Ltd Formulaciones orodispersables.
CN114767871B (zh) * 2022-04-19 2023-04-07 中国工程物理研究院机械制造工艺研究所 介孔硅载药体系及制备方法和介孔硅载药
CN119925640A (zh) * 2025-02-13 2025-05-06 国家卫生健康委科学技术研究所 一种控释药物组合物的制备方法及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2769854B1 (fr) * 1997-10-21 2000-03-31 Prographarm Lab Nouveau procede d'obtention de microspheres et les produits ainsi realises
US7354601B2 (en) * 2003-05-08 2008-04-08 Walker Stephen E Particulate materials
US20050220825A1 (en) * 2004-03-10 2005-10-06 Adrian Funke Molecular dispersions of drospirenone
WO2006048895A1 (en) * 2004-11-08 2006-05-11 Rubicon Research Pvt. Ltd. Aqueous pharmaceutical coating
DE102005015128B4 (de) * 2005-03-31 2008-12-11 Bayer Schering Pharma Aktiengesellschaft Wafer enthaltend Steroidhormone
WO2007041079A2 (en) * 2005-09-30 2007-04-12 Alza Corporation Banded controlled release nanoparticle active agent formulation dosage forms and methods
DE102006003512A1 (de) * 2006-01-24 2007-08-02 Bayer Schering Pharma Ag Plättchenförmige Arzneimittel zur transbukkalen Applikation von Arzneistoffen

Also Published As

Publication number Publication date
EP2331067A1 (en) 2011-06-15
CR20110072A (es) 2011-03-30
WO2010015713A1 (en) 2010-02-11
IL210590A0 (en) 2011-03-31
JP2011530499A (ja) 2011-12-22
DOP2011000049A (es) 2011-03-15
MX2011001519A (es) 2011-03-29
ZA201101737B (en) 2013-08-28
CO6351709A2 (es) 2011-12-20
PE20110573A1 (es) 2011-08-12
CA2732211A1 (en) 2010-02-11
CN102119021A (zh) 2011-07-06
KR20110044752A (ko) 2011-04-29
MA32538B1 (fr) 2011-08-01
ECSP11010815A (es) 2011-03-31
UY32041A (es) 2010-03-26
AU2009279053A1 (en) 2010-02-11
US20110293720A1 (en) 2011-12-01
EA201100304A1 (ru) 2011-08-30
SV2011003835A (es) 2011-07-01
TW201008569A (en) 2010-03-01
BRPI0917030A2 (pt) 2017-03-21

Similar Documents

Publication Publication Date Title
AR072933A1 (es) Sistema de administracion de drogas con contenido de progestina
UY37326A (es) Dispersiones sólidas extruidas por fusión que contienen un agente inductor de apoptosis
AR115939A2 (es) Composición que contiene palmitoil-etanolamida ultra-micronizada
CL2016001031A1 (es) Forma de dosificación de liberación inmediata que evita el abuso, que comprende partículas de núcleo recubiertas y una matriz; su uso para preparar un medicamento útil para prevenir, aliviar o aminorar un nivel de dolor y para prevenir el abuso de un fármaco analgésico narcótico, entre otros.
WO2008058145A3 (en) Therapeutic intra-vaginal devices &amp; methods
AR070379A1 (es) Sistema de administracion de drogas con efecto estabilizante
MX2010006694A (es) Formulacion de liberacion controlada, preventiva de mal uso.
UY31957A (es) Metodo anticonceptivo mejorado
CL2008001966A1 (es) Composicion de disolucion oral que comprende lamotrigina,en forma de particulas con lamotrigina recubiertas con una capa para enmascarar el sabor y granulos que comprenden un desinfectante y un alcohol de azucar y/o un hidrato de carbono; metodo de preparacion;uso para tratar trastornos del humor y prevencion de ataques.
CL2011002968A1 (es) Forma de dosificacion de extrusion por fusion caliente de un ingrediente activo (a) incluido en una matriz que comprende un polimero (c), que el nucleo presenta una orientacion morfologica ortogonal respecto a la direccion longitudinal de extension de la forma de dosificacion; y su procedimiento de preparacion.
WO2012034079A3 (en) Macrolide dosage forms
AR077411A2 (es) Forma de dosificacion farmaceutica solida, con lopinavir y ritonavir, y proceso para su preparacion.
PE20161410A1 (es) Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
CL2011003327A1 (es) Composicion farmaceutica que comprende finafloxacina y un agente antiinflamatorio; uso en el tratamiento de infecciones oftalmicas, oticas o nasales.
MX2014008284A (es) Formulacion de liberacion retardada para reducir la frecuencia de orinar y metodos de uso de esta.
MX2012013021A (es) Formulaciones resistentes a alcohol.
CL2012003105A1 (es) Bacteria comensal geneticamente diseñada, del tracto genital femenino que expresa un agente anti espermatozoide; composicion que comprende dicha bacteria; uso de dicha composicion para la reduccion de la incidencia de embarazo en una poblacion femenina; dispositivo de insercion intravaginal.
MX2019003039A (es) Forma de dosificacion de alivio prolongado.
NZ712159A (en) Antiemetic extended release solid dosage forms
AR070375A1 (es) Sistemas de administracion de drogas que contienen estradiol
HK1256814A1 (zh) 用於在药物中使用的胶体颗粒
WO2007089926A3 (en) Oxcarbazepine pharmaceutical formulation and its method of preparation, wherein oxcarbazepine has a broad and multi-modal particle size distribution
CL2015001368A1 (es) Metodo para anticoncepcion controlada que comprende administrar una preparacion farmaceutica que comprende levonorgestrel y un inhibidor de la cox; uso de la composicion farmaceutica en la anticoncepcion &#34;a la carta&#34;.
CL2011000270A1 (es) Forma de dosificacion oral individual en forma de una matriz de pelicula delgada (grosor igual o menor a 300 um) soluble en agua que comprende un polimero de matriz soluble en agua y particulas de tamaño d90 menor de 280 um que comprenden una progestina y un agente protector, util en la inhibicion de la ovulacion.
BR112012013823A2 (pt) &#34;formulação farmacêutica parenteral em suspensão, de liberação prolongada&#34;

Legal Events

Date Code Title Description
FA Abandonment or withdrawal